middle.news
Recce Pharmaceuticals Advances RECCE 327 Phase 3 Trials with Strategic Licensing and Patent Wins
7:16pm on Monday 31st of August, 2026 AEST
•
Healthcare
Read Story
Recce Pharmaceuticals Advances RECCE 327 Phase 3 Trials with Strategic Licensing and Patent Wins
7:16pm on Monday 31st of August, 2026 AEST
Key Points
Operating loss reduced 30% to AUD 14.96 million
Phase 3 diabetic foot infection trials active in Indonesia and Australia
Non-binding licensing term sheet signed for MENA region
Patents granted in Hong Kong, Brazil, and other jurisdictions
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE